Arcus Biosciences(NYSE) RCUS

Arcus makes new medicines to help people fighting cancer and immune diseases. The company creates pills and injections that teach the body how to find and stop tumors. These treatments aim to give patients better options than current standard therapies.

Fighting Cancer with Molecules

• Casdatifan: Oral pill that blocks HIF-2α (a protein that helps kidney cancer cells survive and spread); currently in late-stage testing.
• Quemliclustat: Small-molecule treatment that inhibits CD73, an enzyme that prevents the immune system from attacking tumors; focusing on pancreatic cancer.
• Domvanalimab: Engineered antibody designed to block TIGIT (an immune-stopping receptor) to help immune cells fight cancer more effectively.
• Zimberelimab: Therapy that targets the PD-1 pathway to help the body recognize and destroy cancer cells across different tumor types.
• Early Pipeline: Research programs focusing on oral pills to treat inflammatory skin conditions like hives and other autoimmune disorders.

Strategic Moves and Partners

• Extended the collaboration with Gilead Sciences to include research on inflammatory and autoimmune diseases.
• Partnered with AstraZeneca to evaluate new combination therapies for patients with Stage 3 lung cancer.
• Signed licensing deals with Taiho Pharmaceutical to develop and sell cancer treatments in Japan and other Asian markets.
• Completed patient enrollment for a Phase 3 study of quemliclustat in advanced pancreatic cancer in September 2025.

Why the Tech Matters

Arcus focuses on creating small-molecule drugs that patients can take as pills to replace or improve upon traditional injections. This internal discovery work is supported by a long-term collaboration with Gilead Sciences for funding and global development.

Performance by the Numbers

• Revenue reached $33 million in Q4 2025, up 26.9% from Q4 2024.
• Market capitalization hit $2.6 billion in Q4 2025, up 87.4% year-over-year.
• Operating loss was $114 million in Q4 2025, a 10.7% increase from the previous year.
• Free cash flow was negative $121 million in Q4 2025, compared to negative $101 million in Q4 2024.

The Big Picture

Arcus has evolved from a research firm into a clinical-stage developer with several products in final Phase 3 testing. Its strategy combines internal drug discovery with deep technical partnerships to address complex diseases.